Clinical Trial Update: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates bortezomib- or carfilzomib-based regimens with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Decadron (Dexamethasone)
• Kyprolis (carfilzomib)
• Revlimid (lenalidomide)
• Velcade (bortezomib)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Plasma Cell Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING